HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Export rule enforcement

This article was originally published in The Rose Sheet

Executive Summary

As it considers changes to the reg, FDA will continue to "exercise enforcement discretion" on requirement in its export notification and recordkeeping rule that records for exported cosmetics or foods be made available to the agency for inspection. Also suspended is mandate that marketers of all regulated products prepare a notarized certification that an exported product does not conflict with the laws of the importing country. Enforcement of two provisions earlier was postponed until July 19 in response to a joint request by CTFA and the Grocery Manufacturers of America (1"The Rose Sheet" July 1, 2002, p. 8). In a July 22 letter to the groups' outside counsel, Peter Barton Hutt (Covington & Burling), FDA said it may issue an advanced notice of proposed rulemaking to seek public comment...

You may also be interested in...



Export Rule Records Inspection Enforcement For Cosmetics Suspended – FDA

FDA will temporarily refrain from enforcing the provision of its export notification and recordkeeping rule that requires companies to make records for cosmetics or foods exported under the law available to the agency during an inspection

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel